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A B S T R A C T
Purpose
This study investigated the long-term probability of developing a second cancer in a large pooled
cohort of patients treated with surgery with or without radiotherapy (RT).
Patients and Methods
All second cancers diagnosed in patients included in the TME, PORTEC-1, and PORTEC-2 trials
were analyzed. In the TME trial, patients with rectal cancer (n  1,530) were randomly allocated
to preoperative external-beam RT (EBRT; 25 Gy in five fractions) or no RT. In the PORTEC trials,
patients with endometrial cancer were randomly assigned to postoperative EBRT (46 Gy in 2-Gy
fractions) versus no RT (PORTEC-1; n  714) or EBRT versus vaginal brachytherapy (VBT;
PORTEC-2; n  427).
Results
A total of 2,554 patients were analyzed (median follow-up, 13.0 years; range 1.8 to 21.2 years). No
differences were found in second cancer probability between patients who were treated without
RT (10- and 15-year rates, 15.8% and 26.5%, respectively) and those treated with EBRT (10- and
15-year rates, 15.4% and 25.6%, respectively) or VBT (10-year rate, 14.9%). In the individual trials,
no significant differences were found between treatment arms. All cancer survivors had a higher
risk of developing a second cancer compared with an age- and sex-matched general population.
The standardized incidence ratio for any second cancer was 2.98 (95% CI, 2.82 to 3.14).
Conclusion
In this pooled trial cohort of  2,500 patients with pelvic cancers, those who underwent EBRT or
VBT had no higher probability of developing a second cancer than patients who were treated with
surgery alone. However, patients with rectal or endometrial cancer had an increased probability of
developing a second cancer compared with the general population.
J Clin Oncol 33:1640-1646. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Cancer survivors are at increased risk of developing
a second cancer compared with the general popula-
tion.1 This increased risk has been explained by sev-
eral factors, such as lifestyle factors, genetic
susceptibility, and administered chemotherapy or
radiotherapy (RT). In a large US SEER-based study,
RT was found to be related to a relatively small
proportion (8%) of second cancers; most second
cancers were related to other factors.2 Increased risk
for an RT-related second cancer was found with
increasing time since treatment andwith decreasing
age at diagnosis.
During the last decades, the role of (neo) adju-
vant RT for rectal and endometrial cancers has been
investigated in several large trials. For both rectal
andendometrial cancers, external-beamRT(EBRT)
increased locoregional control, but this did not
translate into an improvement in overall survival.3-6
The benefit of EBRT for local control should there-
fore be balanced against the risk of adverse effects,
such as long-lasting treatment-related bowel symp-
toms and RT-related second cancers. Several large
studies have assessed the risk of a second cancer in
patients treated with RT after surgery for rectal or
endometrial cancer, with varying results.7-10 Al-
though some studies have found an increased risk of
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developing a second cancer after RT,7 especially in patients treated at
younger ages,8 others have reported that RT did not lead to overall
differences in second cancer risk.9,10
The PORTEC-1 (PostOperative RadiationTherapy in Endome-
trial Carcinoma 1) and PORTEC-2 and TME (TotalMesorectal Exci-
sion) trials have had amajor impact on guidelines for (neo) adjuvant
RT for endometrial and rectal cancers, respectively. These three ran-
domized trials together included  2,500 patients, with long and
complete follow-up information for patients with rectal or endome-
trial cancerwho receivedEBRTorvaginal brachytherapy (VBT) to the
pelvic region, compared with patients treated without RT.3,4,11 The
databases from these large randomized trials were combined to eval-
uate the long-termprobability of developing a second cancer after the
primary rectal or endometrial cancer in patients treated with or with-
out pelvic RT.
PATIENTS AND METHODS
Patients and Treatment
In themulticenter TME trial, 1,530Dutch rectal patients were randomly
assigned to preoperative EBRT followed by standardized total mesorectal
excision (TME) surgery or TME alone between January 1996 and December
1999. Details of the study design have been described previously.4,12 Eligible
patients had a clinically resectable adenocarcinoma, without evidence of dis-
tant metastases, and with an inferior tumor margin below the level of S1/S2
andwithin 15 cm from the anal verge. Patients allocated to EBRTwere treated
with a total dose of 25Gy in five fractions delivered over 5 to 7 days by a three-
or four-field technique.4,12
In the multicenter PORTEC-1 trial, 715 patients with endometrial ade-
nocarcinomawere enrolledbetween June 1990 andDecember 1997.Details of
the PORTEC-1 trial have been reported elsewhere.3,13 All patients underwent
total extrafascial hysterectomy with bilateral salphingo-oophorectomy without
lymphadenectomy and were randomly assigned to postoperative EBRT or no
additional treatment (noRT). Eligible patients had postoperative stage I (accord-
ingtoInternationalFederationofGynecologyandObstetrics1988stagingsystem)
endometrial adenocarcinomaandeithergrade1diseasewithdeep(50%)myo-
metrial invasion, grade 2 diseasewith any invasion, or grade 3with superficial (
50%)invasion.PatientsallocatedtoEBRTweretreatedwithatotaldoseof46Gyin
23 fractions delivered by an anterioposterior opposed-field (30%) or three- or
four-fieldtechnique(70%).3,13TheEBRTtreatmentvolumeandanatomicregion
were similar for endometrial and rectal cancers.
In the multicenter PORTEC-2 trial, 427 patients with endometrial can-
cer were enrolled between May 2002 and September 2006. Details of the
PORTEC-2 trial have been reported in previous publications.11,14 All patients
underwent total extrafascial hysterectomy with bilateral salphingo-
oophorectomy and were randomly allocated to postoperative EBRT or VBT.
Eligible patients had stage I (according to International Federation of Gyne-
cology and Obstetrics 1988 staging system) endometrial carcinoma with high
or intermediate risk factors (ie, age 60 years, with either 50%myometrial
invasion and grade 1 or 2 disease or 50% invasion and grade 3 disease), or
any age with stage IIA disease (except grade 3 disease with 50%myometrial
invasion). Patients assigned to EBRT were treated with a dose of 46 Gy in 23
fractions. Computerized treatment planning was used with a three-
dimensional conformal ormultiple-field technique, with individual shielding
in all fields. For patients assigned to VBT, the upper half of the vagina was
treated using a vaginal cylinder. Brachytherapy schedules were as follows:
high-dose rate, 21 Gy at 5-mm depth in three fractions of 7 Gy over 2 weeks
(87%); low-dose rate, 30Gy (9%);ormedium-dose rate, 28Gyat 5-mmdepth
in one session (4%).11
An ethics committee approved the design of each trial, and all patients
provided informed consent. Because patients in the TME and PORTEC-1
trials were no longer undergoing active follow-up in 2013, the Dutch Pathol-
ogy Registry of the nationwide network and registry of histopathology and
cytopathology in the Netherlands (PALGA) was used to verify the occurrence
of second cancers.15 When inconsistencies in second cancers were found
between data provided by PALGA and the trial database, patients’ general
practitioners and/or treating hospitals were contacted. Because patients in the
PORTEC-2 trial were still undergoing active follow-up in 2013, second cancer
incidence in these patients was collected from the trial database. In the Neth-
erlands (andatPALGA), theguidelines for thedefinitionofmultipleprimaries
(ie, second cancers) proposed by the International Association of Cancer
Registries and International Agency for Research on Cancer are followed.16
Statistical Methods
All data were analyzed by treatment actually received by patients. In the
TME trial, 82 (11.4%) of 718 patients assigned to no preoperative RT received
(mainly postoperative) EBRT in case of R1 resection, and all 695 patients
assigned to EBRT received EBRT. In the PORTEC-1 trial, six (1.7%) of 360
patients assigned to no RT received EBRT, and 15 (4.2%) of 354 patients
assigned to EBRT did not receive EBRT. In the PORTEC-2 trial, three (1.4%)
and one (0.5%) of 213 patients assigned to VBT received no RT and EBRT,
respectively; five (2.3%) and one (0.5%) of 214 patients assigned to EBRT
receivedVBT andnoRT, respectively.Median follow-up timewas assessed by
employing reverse Kaplan-Meier methodology.17 A competing-risk model
withdeath as a competing eventwasused to estimate the cumulative incidence
(ie, probability) of developing a second primary cancer in the different treat-
mentarms.18Gray’s testwasused toassess the statisticaldifferencebetween the
estimated cumulative incidence of second cancers.19 Time at risk started at
random assignment date and ended at date of occurrence of the first second
cancer, death, or last date of study follow-up, whichever occurred first. For
subgroups, timeat risk endedatdateof occurrenceof thefirst secondcancerof
a specific type, death, or last date of study follow-up. To take the background
incidence of cancers in account, data on the Dutch general population pro-
vided by the Netherlands Cancer Registry were used.20 To compare the num-
ber of second cancers in the cohort under studywith the number of cancers in
the Dutch population, standardized incidence ratios (SIRs) were estimated. A
Poisson regression model was employed to estimate SIRs and confidence
intervals. SIRswere estimatedas the ratiosof theobservedpatients’ occurrence
of first second cancers with the expected occurrence in the Dutch general
population, stratified by age, sex, and calendar time. Because basal cell carci-
nomas are not registered by the Netherlands Cancer Registry, observed basal
cell carcinomas in the trials were excluded from the comparison with the
general population. Absolute excess risks were calculated as the observed
patients’ occurrence of second cancersminus thenumber of expected cancers,
divided by person-years at risk andmultiplied by 10.000. A two-sided P value
less than .05 was considered statistically significant. Analyses were performed
using IBMSPSSStatistics (version20.0; SPSS,Chicago, IL). Estimationof SIRs
was computed in R (version R-2.15.3; http://www.r-project.org). The Mstate
library in R was used for competing-risk analyses.21,22
RESULTS
A total of 2,554 patients from the TME (n 1413), PORTEC-1 (n
714), and PORTEC-2 (n 427) trials were analyzed (Fig 1). Overall
median follow-up time was 13.0 years (range, 1.8 to 21.2 years): 14.0
years (range, 2.0 to 16.0 years) in the TME trial, 12.6 years (range, 2.8
to 21.2 years) in the PORTEC-1 trial, and 7.5 years (range, 1.8 to 10.5
years) in the PORTEC-2 trial. Table 1 summarizes patient and tumor
characteristics. Baseline patient characteristics were equally balanced
among the treatment arms in individual studies.3,4,11
In the pooled cohort of 2,554 patients, 759 cancers were diag-
nosed in 549 patients (21.5%). In the TME trial, 306 patients (21.7%)
developed a second cancer, compared with 196 (27.5%) in the
PORTEC-1 trial and 47 (11.0%) in the PORTEC-2 trial, reflecting the
differences in follow-up among the trials. Themost common cancers
were basal cell carcinomas of the skin (n 268), followed by breast
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(n 75), lung (n 55), and colon cancers (n 52). The distribution
of cancer types is listed in Table 2.
No difference in the probability of developing a second cancer
was found between the treatment arms (10-year rates: no RT, 15.8%;
EBRT, 15.4%; VBT, 14.9%; 15-year rates: no RT, 26.5%; EBRT,
25.6%; P .94; Fig 2A). Similarly, in the individual trials, no differ-
ences were found between treatment arms regarding 10-year rates
(TME trial: no RT, 15.3% v EBRT, 14.8% [Fig 2B]; PORTEC-1 trial:
no RT, 16.9% v EBRT, 17.3% [Fig 2C]; PORTEC-2 trial: VBT, 14.9%
v EBRT, 14.4% [Fig 2D]). Similarly, after exclusion of basal cell carci-
nomas of the skin from the analysis, no statistical significant differ-
ences were found. When pooled treatment groups of all studies
together were compared, no differences were seen in cumulative inci-
dence of development of a second cancer at a specific site, except for
rectosigmoid cancer. However, when excluding the TME patients,
there was no statistical difference in rectosigmoid cancer incidence
between the treatment arms (10-year rates:VBT, 1.6%;noRT, 0.84%;
EBRT, 0.54%; P .10). Specifically, patients who underwent EBRT
didnothavemore secondcancers in the abdominalorpelvic area than
nonirradiated patients (data not shown).
Patients included in the TME,
PORTEC-1, and PORTEC-2 trials
(N = 2,672)
Randomly assigned
(n = 2,555)
Excluded
   Did not meet eligibility criteria
(n = 117)
(n = 117)
Allocated to EBRT
   Received EBRT
   Received no RT
   Received VBT
(n = 1,264)
(n = 1,243)
 (n = 16)
(n = 5)
Allocated to no RT
   Received no RT
   Received EBRT
   Lost to follow-up
(n = 1,078)
(n = 989)
 (n = 88)
(n = 1)
Allocated to VBT
   Received VBT
   Received EBRT
   Received no RT
(n = 213)
(n = 209)
 (n = 1)
(n = 3)
Analyzed in the EBRT group
(n = 1,332)
Analyzed in the no-RT group
(n = 1,008)
Analyzed in the VBT group
(n = 214)
Fig 1. CONSORT diagram. EBRT,
external-beam radiotherapy; PORTEC,
Post Operative Radiation Therapy in Endo-
metrial Carcinoma; RT, radiotherapy;
TME, Total Mesorectal Excision; VBT,
vaginal brachytherapy.
Table 1. Patient Demographic and Clinical Characteristics
Characteristic
Total
(N  2,554)
TME
(n  1,413)
PORTEC-1
(n  714)
PORTEC-2
(n  427)
No. % No. % No. % No. %
Age, years
Median 66 65 66 69
Range 23-92 23-92 41-90 49-89
 60 742 29.1 496 35.1 200 28.0 46 10.8
 60 1,812 70.9 917 64.9 514 72.0 381 89.2
Sex
Male 909 35.6 909 64.3 — — — —
Female 1,645 64.4 504 35.7 714 100 427 100
Treatment
No RT 1,008 39.4 635 44.9 369 51.6 4 0.9
EBRT 1,332 52.2 778 55.1 345 48.3 209 48.9
VBT 214 8.4 — — — 214 50.2
TNM stage
0 25 1.8 25 1.8 — — — —
I 420 29.7 420 29.7 — — — —
II 381 27 381 27 — — — —
III 506 35.8 506 35.8 — — — —
IV 81 5.7 81 5.7 — — — —
FIGO 1998 stage
IB 329 28.8 — — 294 41.2 35 8.2
IC 763 66.8 — — 420 58.8 343 80.3
IIA 49 4.3 — — — — 49 11.5
Abbreviations: EBRT, external-beam radiotherapy; FIGO, International Federation of Gynecology and Obstetrics; PORTEC, Post Operative Radiation Therapy in
Endometrial Carcinoma; RT, radiotherapy; TME, Total Mesorectal Excision; VBT, vaginal brachytherapy.
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Age and Sex
Although patients age 60 years at diagnosis of primary cancer
in general had a higher second cancer probability than those age 60
years (15-year rates: 27.2% v 23.9%, respectively; P .01), there was
nodifference in secondcancerprobabilitybetween treatmentarms for
patients age 60 years, nor between treatment arms for patients age
 60 years. In addition, no differences in cumulative probability of a
second cancer were found between treatment groups in men or
women alone (data not shown).
Comparison With General Population
SIR based on all included patients for all types of second cancers
was 2.98 (95% CI, 2.82 to 3.14), which results in 154 excess cases per
10.000 patients per year, as compared with a matched general popu-
lation. SIR based on all patients age 60 years at diagnosis was 5.47
(95%CI,4.73 to6.31), andSIRbasedonallpatients age60yearswas
2.76 (95%CI, 2.60 to 2.93). All SIR and absolute excess risk values are
listed in Table 3.
DISCUSSION
In this pooled analysis of 2,500 patients with pelvic cancers treated
in three large randomized trials, theprobabilityofdevelopinga second
cancer was not different between patients treated with or without RT.
However, patients treated for rectal or endometrial cancer had a
higher probability of developing a second cancer compared with the
general population, stratified by age, sex, and calendar time.
Strengths of this pooled analysis of the TME, PORTEC-1, and
PORTEC-2 trials are the large groupof patientswithpelvic cancers (N
 2,554) and the random treatment allocation, ensuring that trial
groups were comparable with regard to lifestyle factors, genetic sus-
ceptibility, age, and other prognostic factors. Follow-up information
of trial patients was complete, and second tumors were verified using
the Dutch Pathology Registry.
A possible limitation of the study is the difference in total EBRT
dose. The biologic effective dose using / 3 was 46 Gy in the
PORTEC trials, comparedwith 40Gy in theTME trial.Nodifferences
were found in development of a second cancer at a specific site or in
development of sarcomas. Because the rectum was removed in TME
patients, an analysis was performed in which TME patients were
excluded. This analysis showed no statistical difference between treat-
ment arms for rectosigmoid cancer, probably because of the smaller
sample size. Furthermore, a relatively small number of patients (29%)
were age 60 years at random assignment. In the Dutch population,
the incidence of cancer is highest in those between ages 60 and 80
years,20 which is reflected in this pooled cohort, with the majority of
patients age 60 years (71%), making it a representative cohort for
this analysis.
Theoccurrenceofa secondcancerhasalsobeenanalyzed inother
randomized trials.7,8 Patients with rectal cancer in the Uppsala trial
and Swedish rectal cancer trial were treatedwith pre- or postoperative
EBRTor surgery alone. In these trials,more second cancers developed
in the EBRT group (stratified relative risk [RR], 1.85; 95%CI, 1.23 to
2.78), and an increased risk of a second cancer was found in the
irradiated group for organs in ornear the irradiated volume (stratified
RR, 2.04; 95% CI, 1.10 to 3.79). Actuarial life-table procedures were
used to calculate the cumulative proportion of second cancers.7 In
another randomized controlled trial, 568 patients with stage I endo-
metrial cancer were randomly allocated to VBT followed by EBRT or
VBTalone.An increased riskof a secondcancerwas foundafterEBRT
(hazardratio [HR],1.42; 95%CI,1.01 to2.00), andanevenhigher risk
was found in women treated with EBRT who were age 60 years at
Table 2. Second Cancers in Patients in TME, PORTEC-1, and PORTEC-2 Trials
Cancer Type
All Trials TME Trial PORTEC-1 Trial PORTEC-2 Trial
EBRT
(n  1,332)
No RT
(n  1,008)
VBT
(n  214)
EBRT
(n  778)
No RT
(n  635)
EBRT
(n  345)
No RT
(n  369)
EBRT
(n  209)
No RT
(n  4)
VBT
(n  214)
No. % No. % No. % No. % No. % No. % No. % No. % No. % No. %
Any 394 100.0 336 100.0 29 100.0 251 100.0 205 100.0 121 100.0 130 100.0 22 100.0 1 100.0 29 100.0
Hematologic 18 4.6 17 5.1 3 10.3 10 4.0 11 5.4 5 4.1 6 4.6 3 13.6 0 0 3 10.3
Skin 178 45.2 154 45.8 6 20.7 136 54.2 95 46.3 39 32.2 59 45.4 3 13.6 0 0 6 20.7
Breast 31 7.9 38 11.1 6 20.7 3 1.2 10 4.9 24 19.8 27 20.8 4 18.2 1 100 6 20.7
Respiratory 34 8.6 21 6.2 3 10.3 22 8.8 15 7.3 9 7.4 6 4.6 3 13.6 0 0 3 10.3
GI 68 17.3 41 12.2 7 24.1 35 13.9 24 11.7 27 22.3 17 13.1 6 27.3 0 0 7 24.1
Colon 30 22 0 17 14 10 8 3 0 0
Rectosigmoid 3 4 5 0 0 2 4 1 0 5
Rectal 6 2 1 1 1 5 1 0 0 1
Other 29 13 1 17 9 10 4 2 0 1
Urogenital 50 12.7 45 13.4 2 6.9 35 13.9 41 20.0 13 10.7 4 3.1 2 9.1 0 0 2 6.9
Urinary
bladder 19 16 1 10 14 8 2 1 0 0 1
Prostate 16 16 0 16 16 — — — — —
Corpus uteri 3 4 0 3 4 0 0 0 0 0
Ovarian 2 1 0 1 1 1 0 0 0 0
Other 10 8 1 5 6 4 2 1 0 1
Other 15 3.8 20 6.0 2 6.9 10 4.0 9 4.4 4 3.3 11 8.5 1 4.5 0 0 2 6.9
Abbreviations: EBRT, external-beam radiotherapy; PORTEC, Post Operative Radiation Therapy in Endometrial Carcinoma; RT, radiotherapy; TME, Total Mesorectal
Excision; VBT, vaginal brachytherapy.
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diagnosis (HR, 2.02; 95% CI, 1.30 to 3.15).8 In this analysis, in which
actuarial life-tableprocedureswere alsoused, deathwasnot taken into
accountasacompetingevent.Therefore, theprobabilityofdeveloping
a second cancer was overestimated because of the number of patients
who died before experiencing a second cancer.23 Other nonrandom-
ized studies haveused competing-riskmodels to analyze the incidence
of second cancers. In a retrospective cohort study, data from 69,739
patients with endometrial cancer from the US SEER cancer registries
wereused.Patients treatedwithEBRTdevelopedmore secondcancers
compared with patients treated without RT (P  .001), especially
colon (P .001), rectal (P .017), bladder (P .001), vaginal (P
.04), and soft tissue cancers (P .014). Patients receiving VBT only
showed an increased risk for a second cancer of the urinary bladder
(P  .006).10 Another large SEER study evaluated the association
between RT and second cancers in 90,502 patients with endometrial
cancer.TheRR fordeveloping a secondcancer afterRTwas1.25 (95%
CI, 1.20 to 1.29), and an increased risk of developing a second cancer
was found in the radiationfield andafter a longer latencyperiod (10
years).24 In contrast, a different study, which used the US SEER regis-
tries to evaluate the association between RT and second cancers in
patients with primary rectal cancer, did not find a significant differ-
ence between irradiated (n 5,641) and nonirradiated patients (n
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Time Since Random Assignment (years)
1.0
0.8
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0.2
A
0 5 10 15 20
No RT
EBRT
VBT
No. at risk
No RT
EBRT
VBT
496
482
8
84
83
0
2
1
0
708
862
157
1,008
1,332
214
Time Since Random Assignment (years)
1.0
0.8
0.6
0.4
0.2
B
0 5 10 15 20
EBRT
No RT
No. at risk
EBRT
No RT
306
310
48
50
0
0
441
431
778
635
Time Since Random Assignment (years)
1.0
0.8
0.6
0.4
0.2
C
0 5 10 15 20
EBRT
No RT
No. at risk
EBRT
No RT
172
186
35
34
1
2
267
277
345
369
Time Since Random Assignment (years)
1.0
0.8
0.6
0.4
0.2
D
0 5 10 15 20
EBRT
VBT
No. at risk
EBRT
VBT
4
8
0
0
0
0
154
157
209
214
Fig 2. Cumulative probability of developing second cancer in (A) all, (B) TME (Total Mesorectal Excision), (C) PORTEC-1 (Post Operative Radiation Therapy in
Endometrial Carcinoma 1), and (D) PORTEC-2 trials. NOTE. Because only four patients were included in no-RT group in the PORTEC-2 trial, these patients are not
represented in panel D. EBRT, external-beam radiotherapy; RT, radiotherapy; VBT, vaginal brachytherapy.
Table 3. SIRs for All Types of Second Cancer
Characteristic Observed Expected SIR 95% CI AER†
All patients 449 151 2.98 2.82 to 3.14 154
Male sex 167 52 3.23 2.98 to 3.50 178
Female sex 282 101 2.78 2.58 to 3.00 140
Age  60 years 121 22 5.47 4.73 to 6.31 151
Age  60 years 328 119 2.76 2.60 to 2.93 163
Abbreviations: AER, absolute excess risk; SIR, standardized incidence ratio.
Excluding basal cell carcinomas.
†Per 10,000 persons per year.
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15,269; HR, 1.02; 95%CI, 0.92 to 1.12). Irradiated patients seemed to
have a significantly decreased rate of second cancers of the prostate
andbreast,whereas the rates for cancersof theurinarybladder,uterine
corpus, and cervix were increased.9 Finally, a SEER registry–based
study of 647,672 patients with different primary cancers found an
increased RR of developing a second cancer after treatment with RT.
RRs were highest for organs that received 5 Gy and increased with
longer follow-uptimeandyoungerageatdiagnosisof thefirstprimary
cancer. However, it was estimated that only 8% of the second
cancers in irradiated patients might have been related to RT, com-
pared with other factors, such as lifestyle factors, genetic suscepti-
bility, and chemotherapy.2
This finding of only a small proportion of second cancers being
attributable to RT might explain why our randomly assigned EBRT
and VBT groups did not develop significantly more second cancers
than patients treated without RT. Furthermore, several studies we
have cited found an increasing risk when follow-up time increased.
Our follow-up time did not go beyond 20 years after diagnosis of the
primary cancer.However, because themedian age of our patients was
66 years at diagnosis, the clinical relevanceof an even longer follow-up
time is limited. Furthermore, in contrast to studies using the SEER
registries, with selection and treatment biases, we investigated the
incidence of second cancers in randomized controlled trials for which
it could be safely assumed that all treatment groups were equal with
regard to lifestyle factors and genetic susceptibility, whichmay not be
the case in retrospective cohort studies.
SIRs found in our study suggest that these patients with rectal or
endometrial cancer had a 3 higher probability of developing a sec-
ond primary cancer, as could be expected based on the incidence of
cancer in a sex- and age-matched general Dutch population. For
patients age 60 years at diagnosis, this probability even increased to
5.5. This higher risk of developing a second cancer is most likely
caused by several etiologic factors, such as lifestyle, environment, and
host factors and interactions and other influences (eg, gene-
environmentandgene-gene interactions).25Etiologic factors involved
in thedevelopmentofaprimarycancerprobablyalsocontribute to the
development of a second cancer. For instance, patients could bemore
susceptible to primary and secondary cancers because of inherited or
acquired genetic factors, like mutations in mismatch repair genes,
TP53, or the Wnt signaling pathway, or because of Lynch syndrome.
However, both for rectal and endometrial cancers, it is estimated that
only 1% to 5% of cancers in unselected patient groups are related to
Lynch syndrome. Therefore, the impact of Lynch syndrome on the
overall burden of second cancers in this cohort is limited. Further-
more, lifestyle factors may also contribute to the development of
cancers (eg, increased body-mass index is associated with increased
risk for rectal, endometrial, and several other cancers).26
In conclusion, in this large pooled cohort of  2,500 patients
from randomized trials with a median follow-up of 13.0 years, no
increased risk of developing a second cancer was found in patients
who underwent pelvic EBRT, which is important for counseling and
shared decision making. In addition, both patients and physicians
should be aware during follow-up that rectal and endometrial cancer
survivors have a 3higher riskof developing a secondprimary cancer
compared with the general population, with basal cell skin, breast,
lung, and colon cancers beingmost common.
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